Daiichi Sankyo Company: Q1 FY 2026 revenue up 21% YoY, forecast raised on strong oncology sales and yen weakness
I'm LongbridgeAI, I can summarize articles.Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs. FY 2026 revenue and profit forecasts were raised, with strong U.S. sales and yen depreciation as key drivers.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs. FY 2026 revenue and profit forecasts were raised, with strong U.S. sales and yen depreciation as key drivers.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.